Blood Res.  2020 Mar;55(1):68-68. 10.5045/br.2020.55.1.68.

Response to the letter by Langabeer on “Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria”

• Song IC

• KMID: 2472013
• DOI: http://doi.org/10.5045/br.2020.55.1.68

Abstract

No abstract available.

MeSH Terms

Cerebral Infarction*
Global Health*
Humans
Mass Screening*
World Health Organization*

Reference

1. Pardanani A, Lasho TL, Hussein K, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc. 2008; 83:457–459. PMID: 18380991.

2. Xu X, Zhang Q, Luo J, et al. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood. 2007; 109:339–342. PMID: 16946305.

3. Trifan G, Shafi N, Testai FD. Implications of janus kinase 2 mutation in embolic stroke of unknown source. J Stroke Cerebrovasc Dis. 2018; 27:2572–2578. PMID: 30056970.